Advertisement

More articles from Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers

  • Serum PD-1 Is Elevated after Pembrolizumab Treatment
    Milena Music, Marco A.J. Iafolla, Annie He Ren, Antoninus Soosaipillai, Ioannis Prassas, Eleftherios P. Diamandis
    Molecular Cancer Therapeutics Oct 2019, 18 (10) 1844-1851; DOI: 10.1158/1535-7163.MCT-19-0132
  • Circulating Tumor DNA from Colorectal Cancer
    In Sil Choi, Shumei Kato, Paul T. Fanta, Lawrence Leichman, Ryosuke Okamura, Victoria M. Raymond, Richard B. Lanman, Scott M. Lippman, Razelle Kurzrock
    Molecular Cancer Therapeutics Oct 2019, 18 (10) 1852-1862; DOI: 10.1158/1535-7163.MCT-18-0965
  • Clinically Applicable lncRNA Profiling in CN-AML
    Dimitrios Papaioannou, Deedra Nicolet, Hatice G. Ozer, Krzysztof Mrózek, Stefano Volinia, Paolo Fadda, Andrew J. Carroll, Jessica Kohlschmidt, Jonathan E. Kolitz, Eunice S. Wang, Richard M. Stone, John C. Byrd, Ramiro Garzon, Clara D. Bloomfield
    Molecular Cancer Therapeutics Aug 2019, 18 (8) 1451-1459; DOI: 10.1158/1535-7163.MCT-18-1125
  • Determine Targeted Therapies of CRC via ctDNA Profiling
    Weiguo Cao, Yaping Xu, Lianpeng Chang, Yuhua Gong, Liren Li, Xianwei Mo, Xin Zhang, Guole Lin, Jiaolin Zhou, Dan Liu, Yuting Yi, Pingping Dai, Chenchen Zhu, Tao Liu, Yuxing Chu, Yanfang Guan, Yongsheng Chen, Jiayin Wang, Xuefeng Xia, Ling Yang, Xin Yi, Yong Cheng
    Molecular Cancer Therapeutics Jun 2019, 18 (6) 1158-1167; DOI: 10.1158/1535-7163.MCT-18-1247
  • Molecular Profiling of Non-Langerhans Cell Histiocytosis
    Filip Janku, Eli L. Diamond, Aaron M. Goodman, Vaijayanthi Kandadai Raghavan, Tamara G. Barnes, Shumei Kato, Omar Abdel-Wahab, Benjamin H. Durham, Funda Meric-Bernstam, Razelle Kurzrock
    Molecular Cancer Therapeutics Jun 2019, 18 (6) 1149-1157; DOI: 10.1158/1535-7163.MCT-18-1244
  • Tissue NGS versus Liquid Biopsy in Breast Cancer
    Rebecca Shatsky, Barbara A. Parker, Nam Q. Bui, Teresa Helsten, Richard B. Schwab, Sarah G Boles, Razelle Kurzrock
    Molecular Cancer Therapeutics May 2019, 18 (5) 1001-1011; DOI: 10.1158/1535-7163.MCT-17-1038
  • SLCO2B1 and Abiraterone in mCRPC
    Andrew W. Hahn, David M. Gill, Austin Poole, Roberto H. Nussenzveig, Sara Wilson, James M. Farnham, Robert A. Stephenson, Lisa A. Cannon-Albright, Benjamin L. Maughan, Neeraj Agarwal
    Molecular Cancer Therapeutics Mar 2019, 18 (3) 726-729; DOI: 10.1158/1535-7163.MCT-18-0739
  • Sequencing cfDNA Enables Immunotherapy Response Monitoring
    Taylor J. Jensen, Aaron M. Goodman, Shumei Kato, Christopher K. Ellison, Gregory A. Daniels, Lisa Kim, Prachi Nakashe, Erin McCarthy, Amin R. Mazloom, Graham McLennan, Daniel S. Grosu, Mathias Ehrich, Razelle Kurzrock
    Molecular Cancer Therapeutics Feb 2019, 18 (2) 448-458; DOI: 10.1158/1535-7163.MCT-18-0535
  • CSC+/partial-EMT+ CTCs in Metastatic Breast Cancer
    Maria A. Papadaki, Giannis Stoupis, Panayiotis A. Theodoropoulos, Dimitris Mavroudis, Vassilis Georgoulias, Sofia Agelaki
    Molecular Cancer Therapeutics Feb 2019, 18 (2) 437-447; DOI: 10.1158/1535-7163.MCT-18-0584
  • miR-454-3p Is a Tumor Suppressor in Glioma
    Naiyuan Shao, Lian Xue, Rong Wang, Kaiming Luo, Feng Zhi, Qing Lan
    Molecular Cancer Therapeutics Feb 2019, 18 (2) 459-469; DOI: 10.1158/1535-7163.MCT-18-0725

Pages